CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
Diabetes Metab J. 2021;45(2):251-259.   Published online March 5, 2021
DOI: https://doi.org/10.4093/dmj.2020.0206

Excel Download

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
Sang Youl Rhee
Diabetes & Metabolism Journal. 2021;45(4):619-620   Crossref logo
Link1 Link2 Link3
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
Guntram Schernthaner
Diabetes & Metabolism Journal. 2021;45(4):615-616   Crossref logo
Link1 Link2 Link3
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
Diabetes & Metabolism Journal. 2021;45(2):251-259   Crossref logo
Link1 Link2 Link3
The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease
Ahmet Turan Isik, Pinar Soysal, Adnan Yay, Cansu Usarel
Diabetes Research and Clinical Practice. 2017;123:192-198   Crossref logo
Link1 Link2
Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
Hikmat Permana, Theo Audi Yanto, Timotius Ivan Hariyanto
Diabetes Research and Clinical Practice. 2023;195:110205   Crossref logo
Link1 Link2
Association Between DPP-4 Inhibitors and COVID-19–Related Outcomes Among Patients With Type 2 Diabetes
Yunha Noh, In-Sun Oh, Han Eol Jeong, Kristian B. Filion, Oriana Hoi Yun Yu, Ju-Young Shin
Diabetes Care. 2021;44(4):e64-e66   Crossref logo
Link1 Link2
89-LB: COVID-19 Outcomes in Patients Who Started GLP1-RAs during Hospitalization
VINCENZO PROVENZANO, DAVIDE BRANCATO, MATTIA FLERES, FRANCESCA PROVENZANO, ANNA R. SALVAGGIO, ALESSANDRO SCORSONE
Diabetes. 2022;71(Supplement_1):   Crossref logo
Link1 Link2
Efficacy and safety of once-weekly GLP-1 RA in patients with type 2 diabetes treated with DPP-4 inhibitor
Masako Murakami, Naoko Hirahara, Hiroshi Morita, Shigekazu Sasaki
Diabetes Research and Clinical Practice. 2016;120:S105   Crossref logo
Link1 Link2
Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
Nina A. Petunina, Anna L. Terekhova, Ekaterina V. Goncharova
Diabetes mellitus. 2016;19(6):511-517   Crossref logo
Link1 Link2
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on m
Ronald Goldenberg, Ira Gantz, Paula J. Andryuk, Edward A. O'Neill, Keith D. Kaufman, Eseng Lai, Yin Na Wang, Shailaja Suryawanshi, Samuel S. Engel
Diabetes, Obesity and Metabolism. 2017;19(3):394-400   Crossref logo
Link1 Link2